Literature DB >> 19031074

Hypotension due to the drug interaction of voriconazole with eplerenone and nifedipine.

Jun Kato, Takehiko Mori, Yukinori Nakamura, Masatoshi Sakurai, Yoshinobu Aisa, Yasuo Ikeda, Shinichiro Okamoto.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2008        PMID： 19031074     DOI： 10.1007/s00228-008-0588-1

Source DB:  PubMed          Journal:  Eur J Clin Pharmacol        ISSN： 0031-6970            Impact factor:   2.953


× No keyword cloud information.
  6 in total

1.  Loss of blood pressure control on withdrawal of fluconazole during nifedipine therapy.

Authors:  B Kremens; E Brendel; M Bald; P Czyborra; M C Michel
Journal:  Br J Clin Pharmacol       Date:  1999-06       Impact factor: 4.335

2.  Frequency of potential azole drug-drug interactions and consequences of potential fluconazole drug interactions.

Authors:  D Tony Yu; Josh F Peterson; Diane L Seger; William C Gerth; David W Bates
Journal:  Pharmacoepidemiol Drug Saf       Date:  2005-11       Impact factor: 2.890

Review 3.  Factors influencing the magnitude and clinical significance of drug interactions between azole antifungals and select immunosuppressants.

Authors:  Aline H Saad; Daryl D DePestel; Peggy L Carver
Journal:  Pharmacotherapy       Date:  2006-12       Impact factor: 4.705

4.  Effects of the selective aldosterone blocker eplerenone versus the calcium antagonist amlodipine in systolic hypertension.

Authors:  William B White; Daniel Duprez; Richard St Hillaire; Scott Krause; Barbara Roniker; Janice Kuse-Hamilton; Michael A Weber
Journal:  Hypertension       Date:  2003-04-07       Impact factor: 10.190

5.  Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis.

Authors:  Raoul Herbrecht; David W Denning; Thomas F Patterson; John E Bennett; Reginald E Greene; Jörg-W Oestmann; Winfried V Kern; Kieren A Marr; Patricia Ribaud; Olivier Lortholary; Richard Sylvester; Robert H Rubin; John R Wingard; Paul Stark; Christine Durand; Denis Caillot; Eckhard Thiel; Pranatharthi H Chandrasekar; Michael R Hodges; Haran T Schlamm; Peter F Troke; Ben de Pauw
Journal:  N Engl J Med       Date:  2002-08-08       Impact factor: 91.245

Review 6.  Voriconazole.

Authors:  LilyAnn Jeu; Frank J Piacenti; Aleksandr G Lyakhovetskiy; Horatio B Fung
Journal:  Clin Ther       Date:  2003-05       Impact factor: 3.393
  6 in total
  2 in total

1.  Severe secondary hyperkalemia and arrhythmia from drug interactions between calcium-channel blocker and voriconazole: a case presentation.

Authors:  Xinju Zhao; Chunyan Zhang; Li Zhu; Bei Wu; Yun Han; Michael Heung; Li Zuo
Journal:  BMC Nephrol       Date:  2021-05-10       Impact factor: 2.388

2.  Acute Kidney Injury from Excessive Potentiation of Calcium-channel Blocker via Synergistic CYP3A4 Inhibition by Clarithromycin Plus Voriconazole.

Authors:  Eikan Mishima; Kazuichi Maruyama; Toru Nakazawa; Takaaki Abe; Sadayoshi Ito
Journal:  Intern Med       Date:  2017-07-01       Impact factor: 1.271
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.